Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial

As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed a phase 3 flop in the KRAS G12C inhibitor’s smaller-op | As Bristol Myers Squibb attempts to convert two accelerated oncology nods for Krazati into traditional FDA approvals, the company has detailed what could be a major stumble in the KRAS G12C inhibitor’s smaller-opportunity indication of colorectal cancer.